SCHEDULE: Canaan Entities Disclose 5.5% Stake in Tyra Biosciences
Beneficial Ownership Report
Canaan XI L.P. and its general partner, Canaan Partners XI LLC, reported beneficial ownership of 5.5% of Tyra Biosciences, Inc. common stock as of December 31, 2025.
Summary
- Canaan XI L.P. and its general partner, Canaan Partners XI LLC, beneficially own 2,930,444 shares of Tyra Biosciences, Inc. common stock.
- This ownership represents approximately 5.5% of the outstanding common stock.
- Canaan 2020+ Co-Investment L.P. Series 7 and its general partner, Canaan Partners 2020+ Co-Investment LLC, beneficially own 443,885 shares of Tyra Biosciences, Inc. common stock.
- This ownership represents approximately 0.8% of the outstanding common stock.
- The beneficial ownership percentages are calculated based on 53,372,098 shares of common stock outstanding as of October 31, 2025, as disclosed in Tyra Biosciences' Quarterly Report on Form 10-Q filed on November 5, 2025.
- The filing is an Amendment No. 2 to a Schedule 13G.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral disclosure, as Schedule 13G filings are routine reports of beneficial ownership and do not inherently convey positive or negative operational news.
Industry Context
StockSavvy.ai notes that institutional investors like Canaan often take significant stakes in biotechnology companies, indicating potential long-term confidence in the company's pipeline or strategic direction. This filing updates their reported ownership.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and liquidity.
Key Dates
| Date | Description |
|---|---|
| 2025-10-31 | Date as of which 53,372,098 shares of Common Stock were outstanding, per Issuer's 10-Q. |
| 2025-11-05 | Date Issuer's Quarterly Report on Form 10-Q was filed with the SEC. |
| 2025-12-31 | Date of event which requires filing of this statement (reporting period end). |
| 2026-02-13 | Signature date of the Schedule 13G Amendment No. 2. |
Keywords
Tyra Biosciences, Canaan XI L.P., Canaan Partners XI LLC, Canaan 2020+ Co-Investment L.P. Series 7, Canaan Partners 2020+ Co-Investment LLC, beneficial ownership, Schedule 13G, common stock, biotechnology, investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.